These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens. Wilson EM; Kattakuzhy S; Sidharthan S; Sims Z; Tang L; McLaughlin M; Price A; Nelson A; Silk R; Gross C; Akoth E; Mo H; Subramanian GM; Pang PS; McHutchison JG; Osinusi A; Masur H; Kohli A; Kottilil S Clin Infect Dis; 2016 Feb; 62(3):280-288. PubMed ID: 26521268 [TBL] [Abstract][Full Text] [Related]
9. Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection. Kinugasa H; Ikeda F; Takaguchi K; Mori C; Matsubara T; Shiraha H; Takaki A; Iwasaki Y; Toyooka S; Yamamoto K Antivir Ther; 2016; 21(1):37-44. PubMed ID: 26115551 [TBL] [Abstract][Full Text] [Related]
10. Challenge to overcome: Nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus. Sato K; Uraoka T World J Gastroenterol; 2018 Oct; 24(38):4304-4310. PubMed ID: 30344416 [TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus resistance to protease inhibitors. Halfon P; Locarnini S J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949 [TBL] [Abstract][Full Text] [Related]
12. Hepatitis C Virus and Antiviral Drug Resistance. Kim S; Han KH; Ahn SH Gut Liver; 2016 Nov; 10(6):890-895. PubMed ID: 27784846 [TBL] [Abstract][Full Text] [Related]
13. HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy. Chayama K; Hayes CN Viruses; 2015 Oct; 7(10):5328-42. PubMed ID: 26473914 [TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus resistance to the new direct-acting antivirals. Esposito I; Trinks J; Soriano V Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1197-209. PubMed ID: 27384079 [TBL] [Abstract][Full Text] [Related]
15. A genotype independent, full-genome reverse-transcription protocol for HCV genotyping and resistance testing. Walker A; Bergmann M; Camdereli J; Kaiser R; Lübke N; Timm J J Clin Virol; 2017 Jun; 91():42-48. PubMed ID: 28463753 [TBL] [Abstract][Full Text] [Related]
16. Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C. Wilson EM; Rosenthal ES; Kattakuzhy S; Tang L; Kottilil S Clin Microbiol Rev; 2017 Jan; 30(1):23-42. PubMed ID: 27795306 [TBL] [Abstract][Full Text] [Related]
17. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. Sarrazin C J Hepatol; 2016 Feb; 64(2):486-504. PubMed ID: 26409317 [TBL] [Abstract][Full Text] [Related]
18. Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. Cuypers L; Ceccherini-Silberstein F; Van Laethem K; Li G; Vandamme AM; Rockstroh JK Rev Med Virol; 2016 Nov; 26(6):408-434. PubMed ID: 27401933 [TBL] [Abstract][Full Text] [Related]
19. Managing HCV treatment failure and the potential of resistance testing in informing second-line therapy options. Loggi E; Vukotic R; Andreone P Expert Rev Anti Infect Ther; 2018 Nov; 16(11):833-838. PubMed ID: 30336699 [TBL] [Abstract][Full Text] [Related]
20. Are we nearing the end in the fight against hepatitis C? Chua JV; Kottilil S Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):499-500. PubMed ID: 28335650 [No Abstract] [Full Text] [Related] [Next] [New Search]